Key facts
- Healome Therapeutics’s last known valuation is $5.1M (Nov 2025).
- It has raised $2.3M; the latest was Early Stage VC ($1.7M) in Nov 2025.
- Notable investors include Innovate UK, SFC Capital, UK Research and Innovation, Empirical Ventures, National Institute for Health and Care Research — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Healome Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Healome Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Healome Therapeutics
Developer of treatments for eye conditions of ocular diseases designed for eye trauma therapeutics. The company offers novel fluid-gel material that flows like a liquid and self-structures into a thin, clear, protective layer over the surface of the eye, which is gradually dispersed, enabling patients to get more effective and longer lasting relief.
- Sector
- Healthcare
- HQ
- Birmingham, United Kingdom
- Founded
- 2021
- Employees
- 4
- Website
- healometx.com/
- Ownership
- Privately Held (backing)
Healome Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Healome Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Healome Therapeutics in its N-PORT filings yet. We sweep new filings monthly.